Application of L-NRB in preparation of medicine for treating amyotrophic lateral sclerosis

By developing L-NRB, inhibiting inflammatory factors and activating P11-Htr4 signaling pathway, the problems of limited efficacy and poor water solubility in ALS treatment were solved, significantly improved the motor function of ALS mice and delayed disease progression, providing new Drugs for treating ALS.

CN119074713AActive Publication Date: 2024-12-06INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411078014.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-12-06
Estimated Expiration
2044-08-07

AI Technical Summary

Technical Problem

ALS currently lacks effective treatments, existing drugs cannot meet clinical needs, and inflammatory response plays an important role in disease progression, and existing drugs such as phthalide have limited efficacy and poor water solubility, which limits the Its application.

Method used

Developed L-NRB as a levoropoptosis by inhibiting the expression of inflammatory factors and activating the P11-Htr4 signaling pathway, for the prevention and treatment of ALS, providing oral, injectable or transdermal dosage forms, including pharmacy acceptable excipients or excipients.

Benefits of technology

L-NRB significantly improved the motor function of ALS mice, reduced the expression of ALS biomarkers in serum and urine, inhibited neuroinflammatory and glial cell activation in the spinal cord, delayed disease progression, and improved ALS patients Quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074713A_ABST
    Figure CN119074713A_ABST
Patent Text Reader

Abstract

The invention provides an application of a hydroxypentyl benzoic acid diester compound L-NRB in treatment of amyotrophic lateral sclerosis. Animal model tests prove that the L-NRB can effectively improve SODA-G93A mouse behavioral indexes, inhibit expression of inflammatory factors, inhibit loss of anterior spinal horn motor neurons and activation of astrocytes and microglia, and improve gastrocnemius muscle pathological conditions. Meanwhile, the L-NRB can inhibit cell apoptosis of the brain of the mouse and activate a P11-Htr4 signal channel. L-NRB has no toxic and side effects in vivo and in vitro; the pharmaceutical composition has the advantages of high safety, small dosage, long-term stability and the like, and is suitable for further development for actual clinical treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of neurodegenerative diseases and biomedicine. Specifically, the present application provides the use of L-NRB in the preparation of a drug for treating amyotrophic lateral sclerosis. Background Art

[0002] Amyotrophic lateral sclerosis (ALS) is a chronic progressive neurodegenerative disease with progressive skeletal muscle weakness, atrophy, fasciculations, bulbar palsy and pyramidal tract signs as the main clinical manifestations. Some ALS patients will have varying degrees of cognitive and behavioral disorders and other manifestations of frontal and temporal lobe involvement. According to the "Chinese Expert Consensus on the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis 2022", ALS is still an incurable disease, and currently available drugs cannot meet the needs of ALS clinical treatment. Therefore, finding new therapeutic drugs is currently a top priority for the treatment of ALS.

[0003] ALS is a motor neuron disease characterized by degeneration of upper and lower motor neurons, and improving motor dysfunction in patients is a core indicator for evaluating the effectiveness of drugs. Approximately 20% of familial cases and 3% of sporadic ALS cases are associated with mutations in the gene encoding superoxide dismutase-1 (SOD1). SOD1-G93A mice express the G93A mutant form of human SOD1 and are often used in ALS-related research. Muscle atrophy is considered a complex process that involves not only the loss of motor neurons, but also the accumulation of misfolded proteins in muscle, oxidative stress, and mitochondrial dysfunction. Therefore, direct treatment of skeletal muscle is more resistant to damage induced by mutant SOD1. Neuroinflammation can be defined as an inflammatory response of the central nervous system to factors that oppose homeostasis. Neuroinflammation is widely present in neurodegenerative diseases and causes damage to neurons and glial cells in a variety of ways. The release of inflammatory factors and the activation of glial cells are the main factors in neuroinflammation. The activation of microglia leads to the release of inflammatory and cytotoxic components, resulting in neuroinflammation and neurodegeneration. At the same time, the activation of astrocytes can lead to the excitotoxicity of glutamate. Therefore, approaches targeting inflammation in ALS patients have considerable therapeutic potential, and the development of targeted therapies that modulate the inflammatory response in ALS patients has the potential to slow or halt disease progression, thereby improving the quality of life of ALS patients.

[0004] N-butylphthalide (NBP) was approved by the China Food and Drug Administration in 2002 for the treatment of acute ischemic stroke. It is the third innovative drug in China with independent intellectual property rights. The "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China (2021 Edition)" describes N-butylphthalide as a drug that improves microcirculation, promotes angiogenesis, and increases cerebral blood flow. However, the limited efficacy and extremely poor water solubility of NBP itself significantly limit the application of NBP. L-NRB is a left-handed product formed by the 1:2 (molar ratio) splicing of the ring-opening product of N-butylphthalide and dextran. According to previous studies by our research group, L-NRB has good activity in treating cerebral ischemia, and its effect is better than that of N-butylphthalide. L-NRB has both neuroprotective and anti-inflammatory effects. Therefore, it is feasible and practical to study its therapeutic effects on neurodegenerative diseases, especially ALS. Summary of the invention

[0005] In one aspect, the present application provides the use of L-NRB in preventing and treating amyotrophic lateral sclerosis, wherein the chemical formula of the L-NRB is as shown in Formula I:

[0006]

[0007] Furthermore, the ALS is ALS with SOD1 gene mutation.

[0008] Furthermore, the drug inhibits the expression of inflammatory factors and the activation of astrocytes and microglia in the spinal cord.

[0009] Furthermore, the drug inhibits apoptosis of brain cells.

[0010] Furthermore, the drug activates the P11-Htr4 signaling pathway in the brain.

[0011] Furthermore, the drug is in oral, injectable or transdermal dosage form.

[0012] Furthermore, the drug is in oral dosage form.

[0013] Furthermore, the medicine also includes pharmaceutically acceptable adjuvants or excipients.

[0014] On the other hand, the present application provides a drug for treating amyotrophic lateral sclerosis, wherein the drug comprises L-NRB, and the chemical formula of the L-NRB is shown in Formula I:

[0015]

[0016] Furthermore, the drug is in oral dosage form.

[0017] The available drug dosage forms of the present application include various injection, oral, and external dosage forms, including but not limited to tablets, capsules, oral liquids, water injections, powder injections, eye drops, transdermal preparations, etc.

[0018] The drugs described in the present application may also include various pharmaceutically acceptable adjuvants or excipients, including but not limited to coating materials, solvents, solubilizers, adhesives, stabilizers, antioxidants, pH adjusters, flavoring agents, and the like.

[0019] The "L-NRB" described in this application refers to a compound having the chemical formula of the following formula I, which is disclosed in the applicant's prior application CN202210205661.2. Its chemical name, CAS number, chemical formula, and various abbreviations all have the same meaning and can be used interchangeably.

[0020]

[0021] This application illustrates that L-NRB treats amyotrophic lateral sclerosis by inhibiting neuroinflammation and activating the P11-Htr4 signaling pathway, and therefore can be used for the further development of drugs for the prevention / treatment of amyotrophic lateral sclerosis, increasing the number of drugs available for the clinical treatment of amyotrophic lateral sclerosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 These are the experimental results in the animal model of amyotrophic lateral sclerosis: Part A is the time on the rod of each group of mice in the rotating rod experiment; Part B is the hanging wire time of each group of mice in the hanging wire experiment; Part C is the forelimb grasping strength of each group of mice in the grasping strength measurement experiment.

[0023] Figure 2 These are the test results of mouse serum and urine: Part A is the determination of NfL content in serum; Part B is the determination of p-NfH content in serum; Part C is the determination of P75ecd content in urine.

[0024] Figure 3 These are the results of Nissl staining and immunohistochemical staining of GFAP and Iba1 in the mouse spinal cord: Part A is a representative picture of Nissl staining of the spinal cord; Part B is a representative picture of immunohistochemical staining of Iba1 in the spinal cord; Part C is a representative picture of immunohistochemical staining of GFAP in the spinal cord; Part D is a statistical graph of Nissl staining of the spinal cord; Part E is a statistical graph of immunohistochemical staining of Iba1 in the spinal cord; Part F is a statistical graph of immunohistochemical staining of GFAP in the spinal cord.

[0025] Figure 4 These are the test results of mouse serum inflammatory factors: Part A is the determination of the content of IL-1β in serum; Part B is the determination of the content of TNF-α in serum; Part C is the determination of the content of IL-6 in serum.

[0026] Figure 5 The results of the length and weight measurement and HE staining of the mouse gastrocnemius muscle: Part A is a representative picture of the mouse gastrocnemius muscle; Part B is the measurement of the length of the mouse gastrocnemius muscle; Part C is the measurement of the weight of the mouse gastrocnemius muscle; Part D is a representative picture of HE staining of the gastrocnemius muscle at 4 hours.

[0027] Figure 6 The results of Tunel staining and Bcl-2 and Bax expression detection in mouse brain: Part A is a representative picture of Tunel staining in mouse brain; Part B is a statistical graph of Tunel staining in mouse brain; Part C is a representative picture of Western Blot of Bcl-2 and Bax in mouse brain; Part D is a statistical graph of Bcl-2 / Bax.

[0028] Fig. 7A This is the PCA diagram of the WT group and the model group in transcriptome sequencing.

[0029] Figure 7B This is the KEGG analysis diagram of the WT group and the model group in transcriptome sequencing.

[0030] Figure 7C This is a heat map of the WT group and the model group in transcriptome sequencing.

[0031] Fig.7D Representative images of Western Blot of Htr4 and P11 in mouse brain.

[0032] Fig. 7E Statistical graphs of the mRNA and protein levels of P11 and Htr4. DETAILED DESCRIPTION

[0033] Example 1 Construction of an animal model of amyotrophic lateral sclerosis and behavioral experiments

[0034] Experimental Materials:

[0035] L-NRB was synthesized by the Chemical Laboratory of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, and synthesized and confirmed with reference to Example 2 in CN202210205661.2. The positive drug Edaravone was purchased from Simcere Pharmaceutical Group Co., Ltd. (Batch No.: 80-220201)

[0036] Sixty male SOD1-G93A mice (B6.Cg-Tg(SOD1*G93A)1Gur, catalog number: GAP2008) and 20 sex-matched non-transgenic mice (WT) were purchased from Changzhou Cavens Laboratory Animal Co., Ltd. Rotarod fatigue tester (catalog number: YLS-4D) and rat and mouse grip strength tester (catalog number: YLS-13A) were purchased from Jinan Yiyan Technology Development Co., Ltd. 40cm×40cm wire mesh (wire width 0.1cm, spacing 0.5cm) was used for the mouse hanging wire experiment. All animals were raised at the Animal Center of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences. All mice were housed in an environment of 22-26℃, 40-70% humidity and 12 hours of alternating dark and light, with free access to water and food. The use of experimental animals complies with the Guide for the Care and Use of Laboratory Animals issued by the National Institutes of Health and the regulations of the Animal Care and Use Committee of the Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences. This experiment was approved by the Animal Welfare and Laboratory Animal Management and Animal Welfare Committee of the Chinese Academy of Medical Sciences and Peking Union Medical College (approval number: SLXD-20230229011).

[0037] Experimental methods:

[0038] Grouping and administration: SOD1-G93A mice were randomly divided into the model group, the low-dose L-NRB drug group (11 mg / kg), the high-dose L-NRB drug group (22 mg / kg) and the positive drug edaravone group (15 mg / kg). The low-dose L-NRB, high-dose L-NRB drug group and the positive drug edaravone group were intraperitoneally injected according to the dose. The WT group and the model group mice were given an equal volume of normal saline. SOD1-G93A and WT mice were administered from 80 days of age, 6 times a week, for 55 days. Behavioral experiments were started 45 days after administration, and the specific steps are as follows:

[0039] Rotarod test: Mice were trained on the rotarod fatigue instrument for 3 days, and the instrument parameters were set as follows: acceleration time 20s, maximum speed 20rpm, and duration 180s. Mice that could stably move on the instrument were selected for measurement. The measurement parameters were set as follows: acceleration time 20s, maximum speed 30rpm, and duration 180s. Each mouse was measured 3 times with an interval of 1h. The highest time on the rod was selected for statistics, and mice that did not fall off within 180s were recorded as 180s.

[0040] Hanging wire experiment: place the mouse in the center of the wire mesh, shake it gently to make it grasp the wire mesh, gently turn the wire mesh over, and record the time it takes for the mouse to fall from the wire mesh. Measure three times in a row with an interval of 1 hour each time. Select the longest hanging wire time for recording. If a mouse does not fall for 90 seconds, record it as 90 seconds.

[0041] Grip strength test: The mouse is placed in the center of the grip board, and then the mouse's tail is gently pulled to prompt the mouse's forelimbs to grasp the grip board. When the mouse firmly grasps the grip board, the mouse's tail is pulled until the mouse gives up the grip. The test is repeated 3 times, with an interval of 1 hour each time, and the maximum grip strength value is recorded.

[0042] Sample collection method: 55 days after administration, mice were killed and serum was collected. The gastrocnemius muscles and spinal cords of 5 mice in each group were fixed, and the brains of the other 15 mice were frozen.

[0043] Experimental results:

[0044] like Figure 1 As shown in Figure 2, the performance of SOD1-G93A mice at 135 days of age in the motor ability test was reduced compared with the WT group. L-NRB treatment significantly improved the behavioral performance of SOD1-G93A mice in the rotarod test ( Figure 1 A). At the same time, after L-NRB injection, grip strength and hanging endurance time increased ( Figure 1 B- Figure 1 C). These data indicate that L-NRB improves motor function in SOD1-G93A mice.

[0045] Example 2 Determination of Serum Nfl, p-NfH and Urine P75ecd Contents in Mice

[0046] Experimental methods:

[0047] Mouse serum was collected and the content of Nfl and p-NfH in the mouse serum was detected by Elisa method according to the instructions of the kit. Mouse urine was collected and the content of P75ecd in the mouse urine was detected by Elisa method according to the instructions of the kit.

[0048] NfL: The mouse light peptide neurofilament protein detection kit (catalog number: m1541258v) purchased from Shanghai ELISA Biotechnology Co., Ltd. was used for detection.

[0049] p-NfH: Detected using the phosphorylated neurofilament heavy chain detection kit purchased from Shanghai Kexing Reagent (Cat. No.: F10714-A).

[0050] P75ecd: Detected using the mouse NGFR / P75ecd rapid detection kit purchased from Biosensis (Cat. No.: BEK-2220-1P).

[0051] Experimental results:

[0052] NfL and p-NfH levels are correlated with the rate of ALS progression. Therefore, we used NfL and p-NfH to reflect the progression of neuronal damage. Figure 2As shown in A-2B, the serum NfL and p-NfH levels of SOD1-G93A mice were increased. L-NRB and edaravone can reduce the levels of NfL and p-NfH in the serum of ALS mice. P75NTR can mediate the apoptosis of damaged neurons during neuronal injury. The extracellular domain of P75NTR (P75ecd) is cleaved after binding to pro-apoptotic ligands. Studies have shown that P75ecd is excreted in the urine after nerve injury. In our study, L-NRB and edaravone inhibited the upregulation of P75ecd in the urine of SOD1-G93A mice ( Figure 2 C). In summary, L-NRB treatment can reduce the expression of ALS biomarkers in serum and urine of ALS model mice and delay the progression of ALS disease.

[0053] Example 3: Nissl staining of mouse spinal cord and immunohistochemical staining of GFAP and Iba1

[0054] Experimental methods:

[0055] The spinal cord of mice was cut at the waist and sliced, and then stained.

[0056] Nissl staining:

[0057] 1. Dewax the paraffin sections to water: put the sections into environmentally friendly dewaxing liquid I for 20 minutes, environmentally friendly dewaxing liquid II for 20 minutes, anhydrous ethanol I for 5 minutes, anhydrous ethanol II for 5 minutes, and 75% alcohol for 5 minutes, and wash with tap water.

[0058] Frozen section rewarming and fixation: Take the frozen sections out of the -20° refrigerator and restore them to room temperature. Fix them with tissue fixative for 15 minutes and then rinse with running water.

[0059] 2. Nissl staining:

[0060] The tissue sections were immersed in the dye solution for 2-5 minutes, washed with water, slightly differentiated with 0.1% glacial acetic acid, and washed with tap water to terminate the reaction. The degree of differentiation was controlled under a microscope. After washing with tap water, the sections were placed in an oven to dry.

[0061] 3. Transparent sealing: Put the slices into clean xylene for 10 minutes and seal with neutral gum.

[0062] 4. Microscope examination, image acquisition and analysis.

[0063] Immunohistochemistry:

[0064] 1. Fixation of frozen sections: Dry the frozen sections at room temperature, bake in a 37°C oven for 10-20 min, fix them in methanol for 20 min, and wash them in PBS (PH7.4) on a decolorizing shaker three times for 5 min each time.

[0065] 2. Antigen repair: See the table above for repair. During this process, prevent excessive evaporation of the buffer and do not dry the slides. After natural cooling, place the slides in PBS (PH7.4) and shake on a decolorizing shaker for 3 times, 5 minutes each time.

[0066] 3. Block endogenous peroxidase: Place the slices in 3% hydrogen peroxide solution and incubate at room temperature in the dark for 25 minutes. Place the slides in PBS (PH7.4) and wash them on a decolorizing shaker for 3 times, each time for 5 minutes.

[0067] 4. Serum blocking: After the slices are dried, use a tissue pen to draw a circle around the tissue, add 3% BSA in the circle to evenly cover the tissue, and block at room temperature for 30 minutes.

[0068] 5. Add primary antibody: shake off the blocking solution, add primary antibody prepared in a certain proportion of PBS on the slice (recombinant anti-GFAP antibody, Sewell Biotechnology, catalog number: GB15100-100, dilution ratio 1:1000; recombinant anti-Iba1 antibody, Sewell Biotechnology, catalog number: GB153502-100, dilution ratio: 1:1000), and lay the slice flat in a humidified box and incubate overnight at 4°C.

[0069] 6. Add secondary antibody: Place the slide in PBS (PH7.4) and shake on a decolorizing shaker for 3 times, 5 minutes each time. After the slices are slightly dried, add the secondary antibody (HRP labeled) of the corresponding species to the primary antibody in the histochemistry kit to cover the tissue and incubate at room temperature for 50 minutes.

[0070] 7. DAB color development: Place the slide in PBS (PH7.4) and shake on a decolorizing shaker for 3 times, 5 minutes each time. After the slices are slightly dried, add freshly prepared DAB color development solution in the circle, and control the color development time under a microscope. The positive color is brown-yellow, and the slices are rinsed with tap water to stop the color development.

[0071] 8. Re-staining of cell nuclei: Re-stain with hematoxylin for about 3 minutes, wash with tap water, differentiate with hematoxylin differentiation solution for a few seconds, rinse with tap water, re-blue with hematoxylin bluing solution, and rinse with running water.

[0072] 9. Dehydration and sealing: Put the slices into 75% alcohol for 5 min-85% alcohol for 5 min-anhydrous ethanol I for 5 min-anhydrous ethanol II for 5 min-n-butanol for 5 min-xylene I for 5 min to dehydrate and make them transparent. Take the slices out of xylene, dry them slightly, and seal them with sealing glue.

[0073] 10. Microscopic examination: Place the sample under a white light microscope (Nikon Instrument Co., Ltd., model: E100) to interpret the results.

[0074] Experimental results:

[0075] Compared with the WT group, SOD1-G93A mice showed loss of spinal motor neurons, and L-NRB could improve neuronal damage ( Figure 3 A, Figure 3 D). Neuroinflammation is a prominent feature of ALS. Compared with the WT group, the number of astrocytes and microglia in the spinal cord of the model group mice increased. L-NRB can inhibit the activation of astrocytes and microglia ( Figure 3 B-3C, 3E-3F).

[0076] Example 4: Determination of the content of inflammatory factors in mouse serum

[0077] Experimental methods:

[0078] Mouse serum was obtained, and the levels of pro-inflammatory factors IL-1β, TNF-α, and IL-6 in the mouse serum were detected by Elisa method according to the instructions of the kit.

[0079] IL-1β: Detection was performed using a mouse IL-1β detection kit purchased from Beijing Huaying Biotechnology Institute (Cat. No. HY-H0001).

[0080] TNF-α: Detection was performed using a mouse TNF-α detection kit (catalog number: HY-H0019) purchased from Beijing Huaying Biotechnology Institute.

[0081] IL-6: Detection was performed using a mouse IL-6 detection kit purchased from Beijing Huaying Biotechnology Institute (Cat. No. HY-H0007).

[0082] Experimental results:

[0083] L-NRB and edaravone injection can inhibit the expression of pro-inflammatory factors IL-1β, TNF-α and IL-6 in serum ( Figure 4 A- Figure 4 C).

[0084] Example 5: Measurement of mouse gastrocnemius muscle length, weight and HE staining

[0085] Experimental methods:

[0086] The gastrocnemius muscle of the right hind limb of the mouse was taken, and its weight was measured with an analytical balance, and its length was measured with a vernier caliper. The gastrocnemius muscle was then placed in a fixative, and then sectioned and HE stained. The HE staining steps are as follows:

[0087] 1. Rewarming and fixation of frozen sections: Take the frozen sections out of the -20℃ refrigerator and restore them to room temperature. Fix them with tissue fixative for 15 minutes and then rinse with running water.

[0088] 2. Pretreatment: The sections were treated in high-definition constant stain pretreatment solution for 1 min.

[0089] 3. Hematoxylin staining: Stain the sections with hematoxylin solution for 3-5 minutes, wash with tap water, differentiate with differentiation solution, wash with tap water, reblue with bluing solution, and rinse with running water.

[0090] 4. Eosin staining: Dehydrate the sections in 95% alcohol for 1 min, and then stain them in eosin solution for 15 s.

[0091] 5. Dehydration and sealing: The slices were placed in anhydrous ethanol I for 2 min, anhydrous ethanol II for 2 min, anhydrous ethanol III for 2 min, n-butanol I for 2 min, n-butanol II for 2 min, xylene I for 2 min, xylene II for 2 min, and sealed with transparent neutral gum.

[0092] 6. Microscope examination, image acquisition and analysis.

[0093] Experimental results:

[0094] Compared with the model group, L-NRB increased the length and weight of the gastrocnemius muscle in SOD1-G93A mice ( Figure 5 A-5C). Figure 5 As shown in D, L-NRB significantly preserved the cross-sectional area of ​​the gastrocnemius muscle.

[0095] Example 6: Tunel staining and expression of Bcl-2 and Bax in mouse brain

[0096] Experimental methods:

[0097] Tunel staining experimental method:

[0098] 1. Fixation of frozen sections: Bake the frozen sections in a 37°C oven for 10-20 minutes, control the moisture, fix them in 4% paraformaldehyde for 30 minutes, and wash them in PBS (PH7.4) on a decolorizing shaker for 3 times, 5 minutes each time.

[0099] 2. Proteinase K repair: After the slices are slightly dried, use a tissue pen to draw a circle around the tissue (to prevent the liquid from flowing away), add proteinase K working solution to the circle to cover the tissue, and incubate in a 37-degree incubator for 20 minutes. Place the slide in PBS (PH7.4) and shake on a decolorizing shaker to wash 3 times, each time for 5 minutes. (Protease K working solution preparation method, stock solution: PBS = 1:9).

[0100] 3. Room temperature balance: After the slices are slightly dried, add buffer to cover the tissue and incubate the buffer at room temperature for 10 minutes.

[0101] 4. Add reaction solution: according to the number of slices and tissue size, take an appropriate amount of TDT enzyme and dUTP in the tunel kit, and mix the buffer in a ratio of 1:5:50, add it to the circle to cover the tissue, lay the slices flat in a wet box, incubate at 37℃ incubator for 1 hour, and add a small amount of water to the wet box to maintain humidity.

[0102] 5. DAPI counterstaining of cell nuclei: Wash the sections with PBS (PH7.4) for 3 times, 5 min each time. After removing PBS, add DAPI staining solution in the circle and incubate at room temperature for 10 min away from light.

[0103] 6. Sealing: Place the slide in PBS (PH7.4) and wash on a decolorizing shaker for 3 times, 5 minutes each time. After the slices are slightly dried, seal them with anti-fluorescence quenching sealing medium.

[0104] 7. Microscopic examination and photography: Observe the slices under a fluorescence microscope and collect images. (DAPI ultraviolet excitation wavelength is 330-380nm, emission wavelength is 420nm, emitting blue light; 488 excitation wavelength is 465-495nm, emission wavelength is 515-555nm, emitting green light;)

[0105] Western Blot experimental steps: Take about 30 mg of mouse cerebral cortex tissue in a 2 ml centrifuge tube, add magnetic beads and 300 μl RIPA lysis buffer containing protease inhibitors and phosphatase inhibitors, homogenize with a tissue homogenizer, let stand at 4°C for 30 minutes, and then centrifuge at 4°C, 12000 rpm, 30 minutes. Aspirate the supernatant, add loading buffer, mix well, and place in a 100°C metal bath for 10 minutes. When loading, 4 μl of sample was added to each well, and electrophoresis was performed at 80V constant voltage for 1.5 hours. The membrane was transferred at 300 mA in an ice water bath for 45 minutes, blocked with 5% skim milk for 2 hours, and incubated with primary antibody overnight (Bcl-2 recombinant antibody was purchased from Abcam, catalog number: Ab182858, dilution ratio 1:2000; anti-Bax polyclonal antibody was purchased from Wuhan Sanying, catalog number: 50599-2-Ig, dilution ratio 1:1000), washed with TBST 3 times, 10 minutes each time, and then incubated with secondary antibody diluted 1:2000 in 5% skim milk for 1 hour, washed with TBST 3 times, 10 minutes each time, and then developed using the E-BLOT contact chemiluminescence imaging system.

[0106] Experimental results:

[0107] Compared with WT mice, the number of Tunel-positive neurons in the cortex of SOD1-G93A mice increased significantly. Compared with the model group, L-NRB treatment improved the upregulation of Tunel-positive neurons ( Figure 6 A- Figure 6 B). At the same time, compared with the model group, L-NRB can reduce the Bcl-2 / Bax ratio ( Figure 6 C- Figure 6 D).

[0108] Example 7: Mouse brain transcriptome sequencing and mechanism verification

[0109] Experimental methods:

[0110] The gene expression profiles in the brains of WT and SOD1-G93A mice were analyzed by RNA sequencing. The cDNA fragments were amplified by PCR and the cDNA library was constructed. Then, the cDNA library was sequenced using the Illumina sequencing platform (Novaseq-PE250). Total RNA was extracted from mouse brain tissue using TRIZOL reagent. Then, we used PrimeScript RT Reagent kit (RR036A; Takara Bio) to synthesize cDNA from RNA. Finally, we used the fluorescence quantification kit (RR820A; TakaraBio) for fluorescence quantitative analysis. Primer sequences are as follows: Htr4: F: TCTGGATGTCCTACTTACCACAG (SEQ ID NO.1), R: GCAGCAGATGGCGTAATACCT (SEQ ID NO.2); P11: F: TTTCACAGGTTTGCAGGCGA (SEQ ID NO.3), R: CACTTTGCCATCTCGGCACT (SEQ ID NO.4); Gapdh: F: AGGTCGGTGTGAACGGATTTG (SEQ ID NO.5), R: GGGGTCGTTGATGGCAACA (SEQ ID NO.6). As described in Example 5, Western Blot experiments were used to determine the expression of Htr4 and P11 in mouse brain (Htr4 polyclonal antibody was purchased from Wuhan Tri-Tac, catalog number: 21165-1-AP; P11 polyclonal antibody was purchased from Wuhan Tri-Tac, catalog number: 11250-1-AP).

[0111] Experimental results:

[0112] KEGG analysis showed that the differentially expressed genes between the WT group and the model group were enriched in the neuroactive ligand-receptor interaction ( Figure 7A-7B ), related genes such as Figure 7C We examined the transcription and expression of Htr4 and its upstream target P11 in the cortex. Our results showed that L-NRB can activate the P11-Htr4 pathway in the brain of SOD1-G93A mice ( Figure 7D-7E ).

[0113] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. Use of L-NRB in the prevention and treatment of amyotrophic lateral sclerosis, wherein the chemical formula of the L-NRB is shown in Formula I:

2. The use according to claim 1, wherein the amyotrophic lateral sclerosis is amyotrophic lateral sclerosis caused by SOD1 gene mutation.

3. The use according to claim 1 or 2, wherein the drug inhibits the expression of inflammatory factors and the activation of astrocytes and microglia in the spinal cord.

4. The use according to claim 1 or 2, wherein the drug improves gastrocnemius muscle pathology.

5. The use according to claim 1 or 2, wherein the drug inhibits apoptosis of brain cells.

6. The use according to claim 1 or 2, wherein the drug activates the P11-Htr4 signaling pathway in the brain.

7. The use according to claim 1 or 2, wherein the drug is in oral, injectable or transdermal dosage form.

8. The use according to claim 7, wherein the drug is in an oral dosage form.

9. The use according to claim 7, wherein the medicine further comprises a pharmaceutically acceptable adjuvant or excipient.

10. A drug for treating amyotrophic lateral sclerosis, It is characterized in that The drug contains L-NRB, and the chemical formula of the L-NRB is shown in Formula I: The drug according to claim 10 , wherein the drug is in an oral dosage form.

Citation Information

Patent Citations

  • Novel quinoline derivative inhibitor

    CN110857293A

  • Quinoline derivative of TAM family kinase inhibitor

    CN112625026A

  • Hydroxypentyl benzoic acid diester compound as well as preparation method and pharmaceutical application thereof

    CN114315585A

  • Application of gastrodin in preventing or treating amyotrophic lateral sclerosis

    CN115813941A

  • Application of mangostin in preparation of medicine for preventing or treating amyotrophic lateral sclerosis

    CN117064875A